A RARE CASE OF ADENOCARCINOMA WHEN ON ADALIMUMAB BIOSIMILAR

Dr. Vikram Haridas* and Dr. Kiran Haridas

ABSTRACT

Ankylosing spondylitis is a chronic inflammatory disease of joints and number of cases burgeoning day by day in the world. Sacroiliitis is the main symbol of the disorder, peripheral joints, and hip and shoulder joints can be involved. It is predominantly associated with HLA B27 gene. The introduction of biological therapy have improved prognosis of patients with ankylosing spondylitis since last decade. Adalimumab is a human monoclonal antibody approved for treatment of ankylosing spondylitis. Here we present a case of 65-year-old male patient with ankylosing spondylitis who was developed adenocarcinoma after treatment of adalimumab.

Keywords: Ankylosing spondylitis, Adalimumab, Adenocarcinoma.